Abstract

There is evidence to suggest that the primary tumor induces the formation of a pre-metastatic niche in distal organs by stimulating the production of pro-metastatic factors. Given the fundamental role of the pre-metastatic niche in the development of metastases, interruption of its formation would be a promising strategy to take early action against tumor metastasis. Here we report an enzyme-activated assembled peptide FR17 that can serve as a “flame-retarding blanket” in the pre-metastatic niche specifically to extinguish the “fire” of tumor-supportive microenvironment adaption. We show that the in-situ assembled peptide nano-blanket inhibits fibroblasts activation, suppressing the remodeling of the metastasis-supportive host stromal tissue, and reversing vascular destabilization and angiogenesis. Furthermore, we demonstrate that the nano-blanket prevents the recruitment of myeloid cells to the pre-metastatic niche, regulating the immune-suppressive microenvironment. We show that FR17 administration effectively inhibits the formation of the pulmonary pre-metastatic niche and postoperative metastasis, offering a therapeutic strategy against pre-metastatic niche formation.

Primary tumors “spread the spark” by establishing a pre-metastatic niche. Here the authors develop an in-situ assembled peptide FR17 to serve as a “flame-retarding blanket” to extinguish the “fire” of the pre-metastatic microenvironment.

Details

Title
Peptide nano-blanket impedes fibroblasts activation and subsequent formation of pre-metastatic niche
Author
Zhou, Yi 1   VIAFID ORCID Logo  ; Peng, Ke 2 ; Bao Xiaoyan 1 ; Wu, Honghui 1 ; Xia Yiyi 1 ; Zhang Zhentao 1 ; Zhong Haiqing 1 ; Dai Qi 3 ; Wu Linjie 1 ; Wang, Tiantian 1 ; Lin Mengting 1 ; Li Yaosheng 1 ; Jiang Xinchi 1 ; Yang Qiyao 3 ; Lu Yiying 1 ; Zhong Xincheng 1 ; Han, Min 4   VIAFID ORCID Logo  ; Gao Jianqing 4 

 Zhejiang University, Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Hangzhou, PR China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 Zhejiang University, Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Hangzhou, PR China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Shengli Clinical Medical College, Fujian Medical University, Department of Anesthesiology, Fuzhou, PR China (GRID:grid.256112.3) (ISNI:0000 0004 1797 9307) 
 Zhejiang University, Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Hangzhou, PR China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Department of Radiation Oncology, Hangzhou, PR China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 Zhejiang University, Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Hangzhou, PR China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Cancer Center of Zhejiang University, Zhejiang University, Hangzhou, PR China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou, PR China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2669223189
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.